» Articles » PMID: 26345199

Long-term Multi-product Facial Regimen in Subjects with Moderate-to-severe Photodamage and Hyperpigmentation

Overview
Date 2015 Sep 9
PMID 26345199
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Photoaged skin is primarily a result of chronic sun exposure. Irregular pigmentation and wrinkling are common clinical manifestations. Monotherapy with retinoids, growth factors, and skin lighteners have proven beneficial. However, long-term treatment with a multi-product facial regimen has not been assessed.

Objectives: This single-center clinical trial was conducted to assess the efficacy and tolerance of a topical multi-product regimen when used by subjects with moderate-to-severe photodamage and hyperpigmentation on the face over a course of 24 weeks.

Methods: Subjects were supplied with a six-product regimen to use on their face (cleanser, growth factor serum, skin brightener, moisturizer, retinol, and sunscreen). Products were used according to specific application instructions. Clinical grading and tolerability assessments were performed at baseline and at follow-up visits at Weeks 4,8,12,18, and 24. Standardized digital photographs were taken and self-assessment questionnaires were conducted. Image analysis for skin-tone evenness and brightness was also conducted.

Results: Seventy-two subjects completed the 24-week study. All clinical efficacy parameters showed statistically significant improvements over baseline at all visits. Plateau effects for these improvements were not seen at 24 weeks. The facial regimen was well-tolerated. Subject questionnaires showed the regimen was highly rated at all visits.

Conclusion: This six-product, comprehensive facial regimen was shown to be clinically effective and well-tolerated for the treatment of moderate-to-severe photodamage and hyperpigmentation over 24 weeks. Additional benefits may occur with continued use.

Citing Articles

Laser and Skin-Care Synergy: A Post-Laser Application of Novel Adaptogenic Moisturizing Serum for Improving Healing and Cosmesis on the Face.

Blyumin-Karasik M, Colon J, Nguyen S, Rosen J J Cosmet Dermatol. 2024; 24(2):e16668.

PMID: 39503217 PMC: 11845916. DOI: 10.1111/jocd.16668.


Antioxidant Skincare Treatment for Hyperpigmented and Photodamaged Skin: Multi-Center, Open-Label, Cross-Seasonal Case Study.

Hooper D, Tedaldi R, Iglesia S, Young M, Kononov T, Zahr A J Clin Aesthet Dermatol. 2023; 16(10):31-38.

PMID: 37915337 PMC: 10617894.

References
1.
Makino E, Herndon J, Sigler M, Gotz V, Garruto J, Mehta R . Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone. J Drugs Dermatol. 2013; 11(12):1478-82. View

2.
Taylor A, Pawaskar M, Taylor S, Balkrishnan R, Feldman S . Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J Cosmet Dermatol. 2008; 7(3):164-8. DOI: 10.1111/j.1473-2165.2008.00384.x. View

3.
Mauricio T, Karmon Y, Khaiat A . A randomized and placebo-controlled study to compare the skin-lightening efficacy and safety of lignin peroxidase cream vs. 2% hydroquinone cream. J Cosmet Dermatol. 2011; 10(4):253-9. DOI: 10.1111/j.1473-2165.2011.00581.x. View

4.
Ortonne J . Pigmentary changes of the ageing skin. Br J Dermatol. 1990; 122 Suppl 35:21-8. DOI: 10.1111/j.1365-2133.1990.tb16121.x. View

5.
Ho E, Trookman N, Sperber B, Rizer R, Spindler R, Sonti S . A randomized, double-blind, controlled comparative trial of the anti-aging properties of non-prescription tri-retinol 1.1% vs. prescription tretinoin 0.025%. J Drugs Dermatol. 2011; 11(1):64-9. View